Loading clinical trials...
Loading clinical trials...
An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and will allow estimation of prostate-specific antigen (PSA) response in men with metastatic castration-resistant prostate cancer (mCRPC).
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Start Date
July 1, 2010
Primary Completion Date
January 1, 2013
Completion Date
March 1, 2016
Last Updated
July 30, 2019
38
ACTUAL participants
TAK-700
DRUG
Docetaxel
DRUG
Prednisone
DRUG
Lead Sponsor
Millennium Pharmaceuticals, Inc.
NCT04550494
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions